Three things to take away
What is the outlook for the Danish and Swedish life sciences sector and how could limited diversification impact growth prospects
What are the three future risk areas life science firms should be aware of in 2023
What can life science firms do to boost growth using scalable production, digitalization and recruitment.
The Nordic countries’ life sciences sector employs 39,000 people in Denmark (1.4% of the total workforce) and 27,000 in Sweden (0.5% of the total workforce). The sector is concentrated in a small number of larger companies.
The short-term outlook is strong. However, this is largely driven by sales of a single new drug, rather than a broader expansion of the sector. This creates uncertainty about longer-term prospects. Meanwhile, regulations, particularly at the European level, present a significant burden for companies, threatening to undermine the profitability of smaller players.
What is the outlook for the Danish and Swedish life sciences sector and how could limited diversification impact growth prospects
What are the three future risk areas life science firms should be aware of in 2023
What can life science firms do to boost growth using scalable production, digitalization and recruitment.
The Nordic countries’ life sciences sector employs 39,000 people in Denmark (1.4% of the total workforce) and 27,000 in Sweden (0.5% of the total workforce). The sector is concentrated in a small number of larger companies.
The short-term outlook is strong. However, this is largely driven by sales of a single new drug, rather than a broader expansion of the sector. This creates uncertainty about longer-term prospects. Meanwhile, regulations, particularly at the European level, present a significant burden for companies, threatening to undermine the profitability of smaller players.
More like this
Sign-up to be notified about future articles from the Sector Resilience Series, and other thoughts, reports or insights from QBE.
Subscribe now
